Case studies

Phase 3 study in ultra-rare disease

How Adnexi accelerated Phase 3 enrollment through targeted digital screening and site matching for an ultra rare disease program.

Results

Patients completed pre-screen
82
Patients completed screening at an active site
46
Patients randomized in 12 months (~30% of trial)
22

Situation

A biopharmaceutical company developing innovative therapies for people with rare debilitating diseases sought to accelerate trial enrollment.

Approach

  • Designed and implemented a compliant patient lead generation program targeting full enrollment
  • Directed patients to a clinical trial website with a digital prescreener
  • Gave authorized clinical trial personnel secure access to patient screening and enrollment data via the Adnexi Portal